CA2913137A1 - Stabilized hypochlorous acid solution and use thereof - Google Patents
Stabilized hypochlorous acid solution and use thereofInfo
- Publication number
- CA2913137A1 CA2913137A1 CA2913137A CA2913137A CA2913137A1 CA 2913137 A1 CA2913137 A1 CA 2913137A1 CA 2913137 A CA2913137 A CA 2913137A CA 2913137 A CA2913137 A CA 2913137A CA 2913137 A1 CA2913137 A1 CA 2913137A1
- Authority
- CA
- Canada
- Prior art keywords
- solution
- divalent cation
- hypochlorous acid
- magnesium
- calcium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- QWPPOHNGKGFGJK-UHFFFAOYSA-N hypochlorous acid Chemical compound ClO QWPPOHNGKGFGJK-UHFFFAOYSA-N 0.000 title claims abstract description 42
- 238000000034 method Methods 0.000 claims abstract description 77
- 230000000845 anti-microbial effect Effects 0.000 claims abstract description 65
- -1 phosphate anion Chemical class 0.000 claims abstract description 53
- 230000008569 process Effects 0.000 claims abstract description 51
- 229910019142 PO4 Inorganic materials 0.000 claims abstract description 47
- 239000010452 phosphate Substances 0.000 claims abstract description 43
- 150000001768 cations Chemical class 0.000 claims abstract description 38
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 33
- 208000015181 infectious disease Diseases 0.000 claims abstract description 16
- 239000004599 antimicrobial Substances 0.000 claims abstract description 12
- 238000012084 abdominal surgery Methods 0.000 claims abstract description 11
- 241000124008 Mammalia Species 0.000 claims abstract description 9
- 238000004519 manufacturing process Methods 0.000 claims abstract description 6
- 239000000243 solution Substances 0.000 claims description 171
- 239000000203 mixture Substances 0.000 claims description 23
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 20
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 19
- 210000000683 abdominal cavity Anatomy 0.000 claims description 18
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 15
- 239000011777 magnesium Substances 0.000 claims description 15
- 229910052749 magnesium Inorganic materials 0.000 claims description 15
- 238000001356 surgical procedure Methods 0.000 claims description 14
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 claims description 12
- 229910000403 monosodium phosphate Inorganic materials 0.000 claims description 12
- 235000019799 monosodium phosphate Nutrition 0.000 claims description 12
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 claims description 12
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 11
- 239000011575 calcium Substances 0.000 claims description 11
- 229910052791 calcium Inorganic materials 0.000 claims description 11
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims description 10
- 235000019341 magnesium sulphate Nutrition 0.000 claims description 10
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 claims description 8
- 239000003002 pH adjusting agent Substances 0.000 claims description 8
- 241000588724 Escherichia coli Species 0.000 claims description 5
- 208000029836 Inguinal Hernia Diseases 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 241000222122 Candida albicans Species 0.000 claims description 4
- 241000079899 Pedipes mirabilis Species 0.000 claims description 4
- 241000607715 Serratia marcescens Species 0.000 claims description 4
- 238000007486 appendectomy Methods 0.000 claims description 4
- 238000012820 exploratory laparotomy Methods 0.000 claims description 4
- 238000002357 laparoscopic surgery Methods 0.000 claims description 4
- 241000194033 Enterococcus Species 0.000 claims description 3
- 108010059993 Vancomycin Proteins 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 claims description 3
- 229960003165 vancomycin Drugs 0.000 claims description 3
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 claims description 3
- 239000007853 buffer solution Substances 0.000 claims 1
- 238000002360 preparation method Methods 0.000 description 15
- 230000009467 reduction Effects 0.000 description 14
- 150000003839 salts Chemical class 0.000 description 14
- 244000005700 microbiome Species 0.000 description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- 230000003139 buffering effect Effects 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 108700024827 HOC1 Proteins 0.000 description 5
- 101100178273 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) HOC1 gene Proteins 0.000 description 5
- 239000002158 endotoxin Substances 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 4
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 4
- 108010013639 Peptidoglycan Proteins 0.000 description 4
- 206010040047 Sepsis Diseases 0.000 description 4
- 239000000460 chlorine Substances 0.000 description 4
- 229910052801 chlorine Inorganic materials 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 229920006008 lipopolysaccharide Polymers 0.000 description 4
- 229920003023 plastic Polymers 0.000 description 4
- 239000004033 plastic Substances 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 208000031729 Bacteremia Diseases 0.000 description 3
- 208000037487 Endotoxemia Diseases 0.000 description 3
- 241000192125 Firmicutes Species 0.000 description 3
- 230000003187 abdominal effect Effects 0.000 description 3
- 229910052783 alkali metal Inorganic materials 0.000 description 3
- 125000000129 anionic group Chemical group 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 125000002091 cationic group Chemical group 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000005868 electrolysis reaction Methods 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 229920001903 high density polyethylene Polymers 0.000 description 3
- 239000004700 high-density polyethylene Substances 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 239000005020 polyethylene terephthalate Substances 0.000 description 3
- 229920000139 polyethylene terephthalate Polymers 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- 230000004797 therapeutic response Effects 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 206010070545 Bacterial translocation Diseases 0.000 description 2
- 206010016825 Flushing Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 206010040070 Septic Shock Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 2
- 230000007375 bacterial translocation Effects 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 239000000645 desinfectant Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 238000011010 flushing procedure Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 229920001684 low density polyethylene Polymers 0.000 description 2
- 239000004702 low-density polyethylene Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- BBMHARZCALWXSL-UHFFFAOYSA-M sodium dihydrogenphosphate monohydrate Chemical compound O.[Na+].OP(O)([O-])=O BBMHARZCALWXSL-UHFFFAOYSA-M 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 206010014824 Endotoxic shock Diseases 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 229920010126 Linear Low Density Polyethylene (LLDPE) Polymers 0.000 description 1
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 1
- 208000034486 Multi-organ failure Diseases 0.000 description 1
- 208000010718 Multiple Organ Failure Diseases 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 229920000122 acrylonitrile butadiene styrene Polymers 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 229910000288 alkali metal carbonate Inorganic materials 0.000 description 1
- 150000008041 alkali metal carbonates Chemical class 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 150000008052 alkyl sulfonates Chemical class 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 150000001642 boronic acid derivatives Chemical class 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000002561 chemical irritant Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000002192 cholecystectomy Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 150000001925 cycloalkenes Chemical class 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000005202 decontamination Methods 0.000 description 1
- 230000003588 decontaminative effect Effects 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 210000005027 intestinal barrier Anatomy 0.000 description 1
- 230000007358 intestinal barrier function Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000004207 intestinal integrity Effects 0.000 description 1
- 230000003870 intestinal permeability Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- WRUGWIBCXHJTDG-UHFFFAOYSA-L magnesium sulfate heptahydrate Chemical compound O.O.O.O.O.O.O.[Mg+2].[O-]S([O-])(=O)=O WRUGWIBCXHJTDG-UHFFFAOYSA-L 0.000 description 1
- 229940061634 magnesium sulfate heptahydrate Drugs 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229960003085 meticillin Drugs 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 210000004303 peritoneum Anatomy 0.000 description 1
- 206010034674 peritonitis Diseases 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000098 polyolefin Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000008227 sterile water for injection Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- ISIJQEHRDSCQIU-UHFFFAOYSA-N tert-butyl 2,7-diazaspiro[4.5]decane-7-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCCC11CNCC1 ISIJQEHRDSCQIU-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N59/00—Biocides, pest repellants or attractants, or plant growth regulators containing elements or inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/20—Elemental chlorine; Inorganic compounds releasing chlorine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Inorganic Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Pest Control & Pesticides (AREA)
- Plant Pathology (AREA)
- Agronomy & Crop Science (AREA)
- Dentistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Environmental Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Toxicology (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361826382P | 2013-05-22 | 2013-05-22 | |
| US61/826,382 | 2013-05-22 | ||
| PCT/US2014/039202 WO2014190184A1 (en) | 2013-05-22 | 2014-05-22 | Stabilized hypochlorous acid solution and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2913137A1 true CA2913137A1 (en) | 2014-11-27 |
Family
ID=51934166
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2913137A Abandoned CA2913137A1 (en) | 2013-05-22 | 2014-05-22 | Stabilized hypochlorous acid solution and use thereof |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US9918477B2 (enExample) |
| EP (1) | EP2999341B1 (enExample) |
| JP (1) | JP6416227B2 (enExample) |
| CA (1) | CA2913137A1 (enExample) |
| MX (1) | MX373524B (enExample) |
| WO (1) | WO2014190184A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0706677A2 (pt) | 2006-01-20 | 2011-04-05 | Oculus Innovative Sciences Inc | métodos de tratamento ou prevenção de sinusite com solução aquosa com potencial de oxirredução |
| EP2999341B1 (en) | 2013-05-22 | 2018-11-28 | Sonoma Pharmaceuticals, Inc. | Stabilized hypochlorous acid solution and use thereof |
| EP3645017A4 (en) | 2017-06-28 | 2021-05-19 | Collidion, Inc. | COMPOSITIONS, PROCEDURES AND USES FOR CLEANING UP, DISINFECTING AND / OR STERILIZATION |
| JP7379342B2 (ja) | 2018-01-14 | 2023-11-14 | コリディオン，インコーポレイテッド | 洗浄、消毒、滅菌、および／または処置のための組成物、キット、方法、および使用 |
| WO2020172363A1 (en) | 2019-02-20 | 2020-08-27 | Biiosmart Technologies Llc | Hypochlorous acid intravenous solution, preparation, and method of use thereof |
| EP4102968A4 (en) | 2020-02-14 | 2024-04-10 | Collidion, Inc. | COMPOSITIONS, KITS, METHODS AND USES FOR CLEANING, DISINFECTING, STERILIZING AND/OR TREATING |
| LU101842B1 (en) | 2020-06-08 | 2021-12-08 | Arnaud Mainnemare | Pharmaceutical Composition for treating or preventing lesions and infections in a mammal |
| US11097945B1 (en) | 2020-11-04 | 2021-08-24 | Cougar Creek Electrolysed Water, Llc | Methods and systems for production of an aqueous hypochlorous acid solution |
| IT202000028082A1 (it) | 2020-11-23 | 2022-05-23 | Md Italy Srl | Composizione, preparazione ed impiego di una miscela a base di bromo per l’igiene perioculare, il trattamento e la prevenzione delle blefariti |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100737951B1 (ko) * | 1999-12-10 | 2007-07-13 | 가오가부시끼가이샤 | 살균제 조성물 |
| JP3554749B2 (ja) * | 2001-02-22 | 2004-08-18 | 株式会社アクシス | 殺菌消毒剤 |
| US20050139808A1 (en) | 2003-12-30 | 2005-06-30 | Oculus Innovative Sciences, Inc. | Oxidative reductive potential water solution and process for producing same |
| JP5528657B2 (ja) | 2003-12-30 | 2014-06-25 | オキュラス イノヴェイティヴ サイエンシズ、インコーポレイテッド | 酸化還元電位水溶液並びにその製造方法および使用方法 |
| US20050196462A1 (en) | 2003-12-30 | 2005-09-08 | Oculus Innovative Sciences, Inc. | Topical formulation containing oxidative reductive potential water solution and method for using same |
| US9168318B2 (en) | 2003-12-30 | 2015-10-27 | Oculus Innovative Sciences, Inc. | Oxidative reductive potential water solution and methods of using the same |
| CN101163492B (zh) | 2005-03-23 | 2013-01-30 | 奥古露丝创新科学公司 | 利用氧化还原电位水溶液治疗2度和3度烧伤的方法 |
| WO2006102680A2 (en) | 2005-03-23 | 2006-09-28 | Oculus Innovative Sciences, Inc. | Method of treating second and third degree burns using oxidative reductive potential water solution |
| JP5907645B2 (ja) | 2005-05-02 | 2016-04-26 | オキュラス イノヴェイティヴ サイエンシズ、インコーポレイテッド | 歯科用途における酸化還元電位水溶液の使用法 |
| BRPI0706677A2 (pt) | 2006-01-20 | 2011-04-05 | Oculus Innovative Sciences Inc | métodos de tratamento ou prevenção de sinusite com solução aquosa com potencial de oxirredução |
| JP6099294B2 (ja) | 2007-03-13 | 2017-03-22 | オキュラス イノヴェイティヴ サイエンシズ、インコーポレイテッド | 一酸化二塩素を含む抗菌溶液ならびにその製造方法および使用方法 |
| WO2010148004A1 (en) | 2009-06-15 | 2010-12-23 | Oculus Innovative Sciences, Inc. | Solution containing hypochlorous acid and methods of using same |
| BR112012006891A2 (pt) | 2009-07-30 | 2019-09-24 | Oculus Innovative Sciences Inc | formulação de hydrogel compreendendo uma solução aquosa com potencial oxidativo redutivo |
| GB2488838A (en) | 2011-03-11 | 2012-09-12 | Biomimetics Health Ind Ltd | A stable antimicrobial aqueous hypochlorous acid solution |
| EP2999341B1 (en) | 2013-05-22 | 2018-11-28 | Sonoma Pharmaceuticals, Inc. | Stabilized hypochlorous acid solution and use thereof |
-
2014
- 2014-05-22 EP EP14801652.0A patent/EP2999341B1/en not_active Not-in-force
- 2014-05-22 WO PCT/US2014/039202 patent/WO2014190184A1/en not_active Ceased
- 2014-05-22 JP JP2016515094A patent/JP6416227B2/ja not_active Expired - Fee Related
- 2014-05-22 MX MX2015016057A patent/MX373524B/es active IP Right Grant
- 2014-05-22 CA CA2913137A patent/CA2913137A1/en not_active Abandoned
- 2014-05-22 US US14/893,448 patent/US9918477B2/en active Active
-
2018
- 2018-03-20 US US15/926,927 patent/US10412969B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US10412969B2 (en) | 2019-09-17 |
| JP6416227B2 (ja) | 2018-10-31 |
| EP2999341B1 (en) | 2018-11-28 |
| MX2015016057A (es) | 2016-03-21 |
| EP2999341A4 (en) | 2016-11-02 |
| US20180206502A1 (en) | 2018-07-26 |
| EP2999341A1 (en) | 2016-03-30 |
| US9918477B2 (en) | 2018-03-20 |
| MX373524B (es) | 2020-04-21 |
| JP2016521684A (ja) | 2016-07-25 |
| WO2014190184A1 (en) | 2014-11-27 |
| US20160120183A1 (en) | 2016-05-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10412969B2 (en) | Stabilized hypochlorous acid solution and use thereof | |
| JP6033082B2 (ja) | 次亜塩素酸を含有する溶液及びその使用方法 | |
| CN102596207B (zh) | 包含氧化还原电位水的水凝胶配制剂 | |
| KR101569134B1 (ko) | 일산화 이염소 함유 항균 용액, 그의 제조 방법 및 사용 방법 | |
| US20090170932A1 (en) | Disinfectant compositions, methods and systems | |
| KR20190105014A (ko) | 아세트산 및 차아염소산을 포함하는 조성물 및 생물막을 치료하는 방법 | |
| CN102335452A (zh) | 一种功能性敷料的配方与制备方法 | |
| US12582123B2 (en) | Compositions, kits, methods and uses for cleaning, disinfecting, sterilizing and/or treating | |
| JP2022536927A (ja) | 微生物増殖を防止するための組成物、キット、方法、および使用 | |
| CN102238955A (zh) | 含有醋酸的血管内留置导管的锁定溶液及容纳有该锁定溶液的容器 | |
| AU2017233581A1 (en) | Device, method and formulation for chemically assisted dissection | |
| JP2020502249A (ja) | バイオフィルムを処置するための酢酸および次亜塩素酸を含む組成物および方法 | |
| RU2809542C1 (ru) | Способ сопроводительной терапии при хирургическом лечении патологических и застарелых переломов | |
| US20220378819A1 (en) | Compositions and methods for aerodigestive treatment | |
| US20250281526A1 (en) | Compositions Comprising Stable Free Available Chlorine Species and Peroxides, Methods of Making and Uses Thereof | |
| EA053228B1 (ru) | Композиции, наборы, способы и применения для очистки, дезинфекции, стерилизации и/или лечения | |
| EA052898B1 (ru) | Способы и применения для получения композиций, стабильно содержащих формы свободного активного хлора и пероксиды | |
| JP2025538176A (ja) | 安定な遊離有効塩素種と過酸化物とを含む組成物、それを製造かつ使用する方法 | |
| EA041951B1 (ru) | Композиция и способ лечения биопленок | |
| MX2010009435A (es) | Solucion electrolizada de super oxidacion con ph neutro y uso de la misma. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |
Effective date: 20200831 |